$0.18
15.26% day before yesterday
Nasdaq, Dec 27, 09:50 pm CET
ISIN
US19207A1088
Symbol
COEP
Sector
Industry

Coeptis Therapeutics Stock price

$0.18
-0.01 7.04% 1M
-0.10 36.29% 6M
-0.60 76.76% YTD
-0.59 76.34% 1Y
-9.81 98.18% 3Y
-9.72 98.16% 5Y
-9.72 98.16% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.03 13.65%
ISIN
US19207A1088
Symbol
COEP
Sector
Industry

Key metrics

Market capitalization $7.49m
Enterprise Value $8.28m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.05
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-11.26m
Free Cash Flow (TTM) Free Cash Flow $-6.91m
Cash position $1.14m
EPS (TTM) EPS $-0.32
P/E forward negative
Short interest 0.44%
Show more

Is Coeptis Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Coeptis Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Coeptis Therapeutics:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Coeptis Therapeutics:

Buy
100%

Financial data from Coeptis Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.03 1.03
3% 3%
-
-1.03 -1.03
3% 3%
-
- Selling and Administrative Expenses 6.20 6.20
68% 68%
-
- Research and Development Expense 3 3
45% 45%
-
-10 -10
50% 50%
-
- Depreciation and Amortization 1.03 1.03
3% 3%
-
EBIT (Operating Income) EBIT -11 -11
47% 47%
-
Net Profit -12 -12
43% 43%
-

In millions USD.

Don't miss a Thing! We will send you all news about Coeptis Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Coeptis Therapeutics Stock News

Neutral
PRNewsWire
one day ago
WEXFORD, Pa. , Dec. 27, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced it will proceed with a 1-for-20 reverse stock split (the "Reverse Split") of its issued and outstanding shares of common stock, par v...
Neutral
PRNewsWire
3 days ago
Coeptis Aims to Bring AI Innovation in Biotechnology and Technology WEXFORD, Pa. , Dec. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company specializing in innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, proudly announces the completion of its acquisition of the NexGenAI Affiliat...
Neutral
PRNewsWire
17 days ago
Coeptis Technologies Signs Binding Letter of Intent to Acquire Key Assets from a Risk Mitigation Software Company with 10,000 customers in over 100 countries , Expanding into the Booming Data Security Sector following the upcoming acquisition of NexGenAI Affiliates Network WEXFORD, Pa. , Dec. 12, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"...
More Coeptis Therapeutics News

Company Profile

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company. It develops innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

Head office United States
CEO David Mehalick
Employees 7
Founded 2017
Website www.coeptistx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today